Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Marine polysaccharides as multifunctional biomaterials for cancer therapy and drug delivery.

Created on 15 Nov 2026

Authors

Hiti Narula, Raj Kamal, Sonia Dhiman, Chander Parkash Dora

Published in

Carbohydrate research. Volume 571. Pages 110170. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Cancer therapy is challenged by tumour heterogeneity, therapeutic resistance, systemic toxicity, poor drug solubility, limited tumour accumulation, and the complex tumour microenvironment. Marine polysaccharides offer distinctive opportunities for addressing these limitations because of their biocompatibility, biodegradability, structural diversity, functional groups, and inherent biological activities. Polysaccharides obtained from marine algae, animals, and microorganisms, including chitosan, alginate, fucoidan, laminarin, carrageenan, ulvan, porphyran, and marine glycosaminoglycans, possess physicochemical properties suitable for biomedical applications. Their antioxidant, anti-inflammatory, antiproliferative, pro-apoptotic, anti-angiogenic, anti-metastatic, and immunomodulatory activities can complement conventional anticancer strategies. These materials can be engineered into nanoparticles, nanogels, micelles, hydrogels, microspheres, polyelectrolyte complexes, and hybrid nanocarriers for controlled and targeted delivery of chemotherapeutic agents, natural bioactives, proteins, peptides, and genetic therapeutics. Particular potential is associated with stimuli-responsive platforms that exploit tumour-associated acidity, reactive oxygen species, redox conditions, or enzymes to regulate therapeutic release. Drug-gene co-delivery approaches further provide opportunities to enhance therapeutic efficacy and address resistance and metastasis. Despite promising preclinical findings, structural variability, source-dependent composition, reproducibility, manufacturing scale-up, formulation stability, safety assessment, and regulatory requirements remain important barriers. Advancing these systems will require rigorous characterisation, standardisation, scalable production, mechanistic investigation, and clinically relevant translational studies to establish their therapeutic value in cancer treatment applications.

PMID:
43033792
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement